Cystic fibrosis-related diabetes and lung disease: an update
Bernadette Prentice, Adam Jaffé, Shihab A. Hameed, Charles F. Verge, Shafagh A. Waters, John Widger
Abstract
The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.
Topics & Concepts
MedicineCystic fibrosis-related diabetesCystic fibrosisDiabetes mellitusLung functionLungDiseaseIntensive care medicineLung diseaseFibrosisPulmonary function testingInternal medicineType 2 diabetesEndocrinologyImpaired glucose toleranceCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchTracheal and airway disorders